Basepoint Wealth’s Bristol-Myers Squibb BMY Stock Holding History

Basepoint Wealth’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$161K	Sell	2,648 -83	-3%	-$4.84K	0.09%	113
2025 Q4	$147K	Buy	+2,731	New	+$131K	0.09%	117
2025 Q2	–	Sell	-4,004	Closed	-$244K	–	105
2025 Q1	$244K	Buy	4,004 +36	+0.9%	+$2.1K	0.19%	83
2024 Q4	$224K	Buy	+3,968	New	+$222K	0.18%	93
2023 Q4	–	Sell	-4,060	Closed	-$236K	–	103
2023 Q3	$236K	Sell	4,060 -64	-2%	-$3.92K	0.19%	90
2023 Q2	$264K	Buy	4,124 +51	+1%	+$3.42K	0.22%	86
2023 Q1	$282K	Buy	4,073 +6	+0.1%	+$423	0.24%	82
2022 Q4	$293K	Buy	4,067 +19	+0.5%	+$1.43K	0.26%	74
2022 Q3	$288K	Buy	4,048 +19	+0.5%	+$1.38K	0.31%	67
2022 Q2	$310K	Sell	4,029 -61	-1%	-$4.65K	0.32%	63
2022 Q1	$299K	Sell	4,090 -130	-3%	-$8.73K	0.28%	62
2021 Q4	$263K	Buy	+4,220	New	+$248K	0.26%	64

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Basepoint Wealth's BMY Position: Q1 2026 in Review

Basepoint Wealth reduced its Bristol-Myers Squibb (BMY) stake by 3% in Q1 2026, selling an estimated $4.84K and leaving 2,648 shares worth $161K. The position accounts for 0.09% of the portfolio, ranked #113.

Basepoint Wealth first reported a position in BMY in Q4 2021 and has held it in 12 quarters since. The position peaked at $310K in Q2 2022. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

Basepoint Wealth held 2,648 shares of Bristol-Myers Squibb worth $161K as of Q1 2026.
Basepoint Wealth sold 83 Bristol-Myers Squibb shares in Q1 2026, an estimated $4.84K.
Bristol-Myers Squibb made up 0.09% of Basepoint Wealth's portfolio in Q1 2026, its #113 holding.
Basepoint Wealth first reported a position in Bristol-Myers Squibb in Q4 2021 and has held it in 12 quarters since.
Basepoint Wealth's Bristol-Myers Squibb position peaked at $310K in Q2 2022.
2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Basepoint Wealth's 13F filing for Q1 2026, filed 7 May 2026.